Agios Q2 FY26 net loss narrows to $100.7 million; revenue more than doubles to $44.75 million - AGIO News | RalliesAgios Q2 FY26 net loss narrows to $100.7 million; revenue more than doubles to $44.75 million
A
AGIO• Quarterly results
- Agios posted a GAAP net loss of $100.7 million, narrowing from $112 million a year earlier.
- GAAP revenue more than doubled to $44.7 million, driven by mitapivat (PYRUKYND and AQVESME) worldwide net revenue of $44.7 million.
- R&D expenses rose to $100.8 million due to a $25 million upfront payment to license cevidoplenib; SG&A climbed to $51.5 million.
Cash position and program updates
- Cash, cash equivalents and marketable securities fell to $964.8 million as of June 30, 2026, from $1.16 billion at the end of 2025.
- Mitapivat sNDA won FDA Priority Review in sickle cell disease with a Nov. 1, 2026 PDUFA date.
- AQVESME reached 442 cumulative U.S. thalassemia prescriptions.
